Neurocrine Biosciences에 대한 매도 수량은 투자자에게 Neurocrine Biosciences의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Neurocrine Biosciences (NASDAQ:NBIX) 주식, 공매도 수량 보고

Neurocrine Biosciences

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Equities

Large Cap

News

Movers

Trading Ideas

AVTR

ILMN

MRNA

NBIX

PYPL

SWKS

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 스카이웍스 솔루션(NASDAQ:SWKS)의 주식은 회사가 1분기 실적을 발표하고 2분기 가이던스를 예상치 이하로 제시한 후 25.99% 하락했다. 애널리스트들은 주가 전망을 수정했다.

에스티 로더, 모더나 및 페이팔 등 지난주 하락한 10개의 대형주 (2월 3일-7일)

BIRK

CHWY

DOCS

KVYO

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

INTC

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SMCI

SNAP

이들 10개 대형주는 8월에 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 슈퍼 마이크로 컴퓨터(NASDAQ:SMCI)의 주식은 8월에 34.89% 하락했다. 이 회사는 10-K 제출을 연기했다.

인텔, 모더나 그리고 달러 제너럴은 8월 최악의 성과를 보인 10개 대형주 중 일부

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

WIIM

Neurocrine Biosciences shares are trading lower after HC Wainwright & Co. and Guggenheim cut their respective price targets on the stock.

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $165 to $163.

Price Target

Analyst Ratings

Guggenheim Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $163

HC Wainwright &amp; Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $190 to $185.

HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $185

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) stock declined 25.99% after the company reported first-quarter earnings and issued second-quarter guidance below estimates. Analysts revised <a href="https://www.benzinga.com//node/43540329" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Estee Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) stock plummeted 22.05%  after the company <a href="https://www.benzinga.com//node/43462736" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Several analysts lowered <a href="https://www.benzinga.com/quote/el/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares tumbled 19.23% after the company missed its fourth-quarter revenue <a href="https://www.benzinga.com//node/43544393" target="_blank" rel="noreferrer noopener">estimate when reporting financial results</a>. Additionally, HC Wainwright &amp; Co. and B of A Securities lowered <a href="https://www.benzinga.com/quote/nbix/analyst-ratings" target="_blank" rel="noreferrer noopener">their respective price forecasts on the stock</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares fell 17.30%, probably after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.&#8217;s nomination to the Senate floor.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) stock was down 16.33% after the company <a href="https://www.benzinga.com//node/43544682" target="_blank" rel="noreferrer noopener">reported fourth-quarter results</a>. Analysts lowered <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) stock decreased 14.23%, probably after President Trump reiterated a pledge to increase oil production.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) shares declined 14.01% after the company reported fourth-quarter results and <a href="https://www.benzinga.com//node/43560312" target="_blank" rel="noreferrer noopener">missed its adjusted EPS estimate</a>.</li>
<li>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) stock tumbled 12.72% after the company reported fourth-quarter results and analysts <a href="https://www.benzinga.com//node/43475080" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>IDEX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) shares fell 12.65% following mixed <a href="https://www.benzinga.com//node/43479651" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>. Analysts revised <a href="https://www.benzinga.com/quote/iex/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) shares declined 12.64% after the company reported first-quarter financial results, issued guidance below <a href="https://www.benzinga.com//node/43509190" target="_blank" rel="noreferrer noopener">estimates and cut its FY25 guidance</a>.</li>
</ol>
Photo by Lets Design Studio via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580845/palantir-super-micro-computer-and-spotify-are-among-top-10-large-cap-gainers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
</ul>

Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

<h3>Gainers</h3>
<ul>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares rose 74.0% to $1.34 during Friday's pre-market session. The market value of their outstanding shares is at $43.8 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 73.54% to $2.69. The market value of their outstanding shares is at $4.1 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 31.55% to $0.21. The market value of their outstanding shares is at $1.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares moved upwards by 23.48% to $71.94. The market value of their outstanding shares is at $13.4 billion. The company's, Q3 earnings came out yesterday. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock rose 13.18% to $3.52. The market value of their outstanding shares is at $61.7 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares moved upwards by 12.78% to $3.97. The market value of their outstanding shares is at $188.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares declined by 24.2% to $1.22 during Friday's pre-market session. The market value of their outstanding shares is at $58.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 17.3% to $5.45. The company's market cap stands at $296.5 million. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares decreased by 16.15% to $126.21. The market value of their outstanding shares is at $12.7 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) stock decreased by 14.9% to $3.03. The company's market cap stands at $168.6 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 13.57% to $9.94. The company's market cap stands at $30.2 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) shares fell 13.02% to $1.27. The market value of their outstanding shares is at $30.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

CYTH

GUTS

NBTX

NVNO

RNXT

STIM

XCUR

12 Health Care Stocks Moving In Friday's Pre-Market Session

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Sector Perform and lowers the price target from $154 to $148.

RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $148

Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and lowers the price target from $157 to $147.

Wedbush Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $147

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $172 to $163.

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $163

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $1.56</a>.
The company reported sales of $627.7 million compared to $515.2 million a year ago, missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43544393/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2024-financial-results-and-provides-finan" rel="noreferrer noopener">consensus of $628.99 million</a>.
Ingrezza fourth quarter and fiscal 2024 net product sales were&nbsp;$615 million&nbsp;and&nbsp;$2.3 billion, respectively.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43273280/neurocrine-obtains-exclusive-rights-for-depression-drug-takeda-reacquires-japan-rights" rel="noreferrer noopener">Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights</a>
Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by strong underlying patient demand and improvement in gross-to-net dynamics.
Crenessity fourth quarter and fiscal 2024 net product sales were&nbsp;$2 million, reflecting initial pharmacy orders following FDA approval in&nbsp;December 2024
Guidance: Neurocrine Biosciences expects 2025 Ingrezza Net Product Sales of $2.5 billion-$2.6 billion.
William Blair writes that Ingrezza&#8217;s 2025 revenue guidance is slightly conservative compared to their 2025 estimate of $2.60 billion and the Street estimate of $2.67 billion, which fell below investor expectations.
Analyst Myles Minter writes that near-term pressures are weighing on the Ingrezza trajectory. The analyst continues to view Ingrezza as the gold-standard pharmacotherapy for tardive dyskinesia (TD), given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.
With Ingrezza still holding 14 years of potential patent protection, William Blair sees a long growth trajectory for the product, but the model addresses near-term competitive pressures ahead of the second-half 2025 salesforce expansion.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/NBIX/analyst-ratings" rel="noreferrer noopener">Outperform rating on Neurocrine</a>.
Analyst Reaction:
<ul>
<li>BofA Securities analyst Tazeen Ahmad maintains Neurocrine Biosciences with a Buy and lowers the price target from $184 to $179.</li>
<li>Needham analyst Ami Fadia reiterates the Hold rating.</li>
<li>HC Wainwright analyst Andrew Fein maintains Neurocrine Biosciences with a Buy and lowers the price target from $190 to $185.</li>
</ul>
Price Action: NBIX stock is down 191% at $121.98 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43566749/spire-global-lands-72m-contract-for-canadian-wildfire-detection-stock-jumps" target="_blank" rel="noreferrer noopener">Spire Global Lands ~$50M Contract For Canadian Wildfire Detection; Stock Jumps</a></li>
</ul>

Analyst Color

Biotech

Earnings

Guidance

Health Care

General

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Neurocrine Biosciences shares are trading lower after the company missed its Q4 revenue estimate when reporting financial results. Additionally, HC Wainwright & Co. and B of A Securities lowered their respective price targets on the stock.

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

B of A Securities analyst Tazeen Ahmad maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $184 to $179.

B of A Securities Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $179

<h3>Gainers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 67.7% to $0.27 during Friday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock moved upwards by 24.42% to $72.49. The company's market cap stands at $13.5 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock increased by 16.49% to $7.77. The market value of their outstanding shares is at $86.2 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 15.25% to $0.68. The company's market cap stands at $2.5 million. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock increased by 14.37% to $1.83. The company's market cap stands at $64.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock moved upwards by 8.62% to $0.65. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) stock decreased by 24.2% to $1.22 during Friday's pre-market session. The company's market cap stands at $58.6 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 21.92% to $2.78. The company's market cap stands at $154.7 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) stock fell 16.55% to $5.5. The market value of their outstanding shares is at $299.2 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock fell 13.57% to $9.94. The market value of their outstanding shares is at $30.2 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 12.26% to $4.08. The market value of their outstanding shares is at $4.9 million. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock declined by 11.65% to $132.98. The market value of their outstanding shares is at $13.4 billion. As per the press release, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBLG

HSDT

LIPO

NTRB

TNFA

Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) just disclosed its Q4 earnings on Thursday, February 6, 2025 at 04:01 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71.
Revenue was up $112.50 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.3, leading to a 3.0% drop share price change the next day.
Here's a look at Neurocrine Biosciences's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.03</td>
<td>1.01</td>
<td>1.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.81</td>
<td>1.63</td>
<td>1.20</td>
<td>1.54</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>600.63M</td>
<td>547.07M</td>
<td>511.97M</td>
<td>518.13M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>622.10M</td>
<td>590.20M</td>
<td>515.30M</td>
<td>515.20M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Neurocrine Biosciences <a href="https://www.benzinga.com/quote/NBIX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Neurocrine Biosciences Q4

Neurocrine Biosciences Sees INGREZZA FY25 Net Product Sales $2.5B-$2.6B

Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) reported quarterly earnings of $1.69 per share which beat the analyst consensus estimate of $1.56 by 8.33 percent. This is a 9.74 percent increase over earnings of $1.54 per share from the same period last year. The company reported quarterly sales of $627.70 million which missed the analyst consensus estimate of $628.99 million by 0.20 percent. This is a 21.84 percent increase over sales of $515.20 million the same period last year.

Earnings Beats

Earnings Misses

Neurocrine Biosciences Q4 2024 Adj EPS $1.69 Beats $1.56 Estimate, Sales $627.70M Miss $628.99M Estimate

AAMI

AFRM

AGCO

AMRK

AMZN

APTV

BILL

CCEC

CIGI

CLFD

CLSK

CRNC

CTLP

EMBC

ENTG

EXPE

EXPO

FARM

FBIN

FTNT

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

INTR

KVUE

LADR

LESL

Laboratory Corporation Of America Holdings

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MPWR

MSGE

MTSI

Earnings Scheduled For February 6, 2025

In the last three months, 7 analysts have published ratings on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a 4.77% increase, the current average has risen from the previous average price target of $161.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1738706415_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$148.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>About Neurocrine Biosciences</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Neurocrine Biosciences: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 24.72%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin is impressive, surpassing industry averages. With a net margin of 20.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.8% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $170 to $185.

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $185

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $147.00...

Wedbush Keeps Their Buy Rating on Neurocrine (NBIX)

Mizuho Securities analyst Uy Ear has maintained their neutral stance on NBIX stock, giving a Hold rating today. Uy Ear's rating is based on several...

Hold Rating on Neurocrine Due to Below-Expectations Financial Performance and Conservative Sales Guidance

H.C. Wainwright lowered the firm's price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza revenue ...

Neurocrine price target lowered to $185 from $190 at H.C. Wainwright

RBC Capital lowered the firm's price target on Neurocrine (NBIX) to $148 from $154 and keeps a Sector Perform rating on the shares. The company's w...

Neurocrine price target lowered to $148 from $154 at RBC Capital

Wedbush analyst Laura Chico lowered the firm's price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the shares. Wi...

Neurocrine price target lowered to $147 from $157 at Wedbush

Neurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences' earnings call ...

Neurocrine Biosciences' Earnings Call: Record Sales & Strategic Growth

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price tar...

Neurocrine (NBIX) Gets a Buy from Evercore ISI

Guggenheim lowered the firm's price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company reported I...

Neurocrine price target lowered to $163 from $165 at Guggenheim

Meeting to be held on February 14 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Neurocrine management to meet with Oppenheimer

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Labcorp Holdings (LH – Research Report) and Neurocri...

Analysts Are Bullish on These Healthcare Stocks: Labcorp Holdings (LH), Neurocrine (NBIX)

Press Releases

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

Comments

Neurocrine Biosciences

매도 수량

Neurocrine Biosciences (NASDAQ:NBIX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌